Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Roche Holding (SWX:ROP) is back in focus after the US Food and Drug Administration granted Priority Review to its supplemental Biologics License Application for Gazyva/Gazyvaro in primary membranous nephropathy, highlighting late stage pipeline momentum.
See our latest analysis for Roche Holding.
Roche Holding’s CHF330.2 share price follows a 5.33% 90 day share price return and a 32.83% 1 year total shareholder return, suggesting recent FDA and diagnostics news is feeding into building momentum rather than fading interest.
If treatments and diagnostics in kidney and liver disease are on your radar, it could be a good moment to scan other opportunities using the healthcare focused 128 healthcare AI stocks
Roche Holding’s strong recent run sits at the crossroads of fresh excitement around its pipeline and a reassessment of its core pharma and diagnostics cash generation. How does that mix compare with what you are paying today?
Most Popular Narrative: 6.5% Undervalued
Roche Holding’s narrative fair value of CHF353.34 sits above the current CHF330.2 share price, pointing to a modest valuation gap built on cash flow strength and pipeline expectations.
Roche is a high-quality, cash-generative pharma leader with:
✅ Strong fundamentals:
• $80B revenue scale
• ~$26B EBITDA
• ~30% margins
✅ Attractive profile:
• Defensive and dividend (~3%)
• Deep pipeline with multiple catalysts
Curious what sits behind that fair value for Roche Holding? The narrative leans heavily on steady revenue growth, firm margins and a future earnings multiple that assumes the current pipeline keeps delivering. The exact mix of those inputs might surprise you.
Result: Fair Value of CHF353.34 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this Roche Holding narrative still hinges on late stage pipeline delivery and exposure to biosimilar pressure, either of which could quickly change sentiment.
Find out about the key risks to this Roche Holding narrative.
Next Steps
If this Roche Holding story seems finely balanced between opportunity and concern, consider reviewing the figures promptly and comparing them with your own perspective by weighing the 5 key rewards and 1 important warning sign
Looking for more investment ideas beyond Roche Holding?
Do not stop at Roche Holding. Broaden your watchlist with other stocks that match your risk appetite, income goals, and quality filters using the Simply Wall Street Screener.